Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease

Kanwal, Fasiha, Kramer, Jennifer R., Li, Liang, Dai, Jianliang, Natarajan, Yamini, Yu, Xian, Asch, Steven M., El‐Serag, Hashem B.·2020·Hepatology
DOI 10.1002/hep.31014

Cited by (320)

Items 301–320 of 320

  1. Impact of metabolic syndrome components on fibrosis severity and mortality in alcohol-related liver disease
    Kodjo-Kunale Abassa, Hongsheng Yu, Shuyan Tan, Mingkai Li, Zhenwei Zhong, Haoxiong Zhou, Yunwei Guo · 2026 · Drug and Alcohol Dependence
  2. Metabolic burden-based clinical-radiological model for predicting postoperative recurrence of hepatitis B-related hepatocellular carcinoma
    Beixuan Zheng, Heqing Wang, Yuyao Xiao, Fei Wu, Chun Yang, Ruofan Sheng, Mengsu Zeng · 2026 · Insights into Imaging
  3. Special Populations
    Robert J. Wong, Massimo G. Colombo, Elisa Pinto, Patrizia Burra · 2026 · Clinics in Liver Disease
  4. Hepatocellular Carcinoma in the Setting of Metabolic Dysfunction Associated Steatotic Liver Disease
    Amanda Su, Jeanne M. Clark, Amy K. Kim · 2026 · Current Hepatology Reports
  5. Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Sonal Kumar, Maria Paula Macedo, Michael Roden, Sangeeta Rao Kashyap · 2026 · Clinics in Liver Disease
  6. Metabolic dysfunction-associated steatotic liver disease and acute leukemias – a literature review and future directions
    Tareq Salah, Maximillian Stahl, Jan Philipp Bewersdorf · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
  7. Clinical and epidemiological aspects of hepatocellular carcinoma in a region of the state of Minas Gerais – Brazil
    Geisa Perez Medina Gomide, PEDRO EMIDIO DE FREITAS NETO, Mariana Silveira Leopoldino, Gabriel Santos Faria de Carvalho, Ana Júlia Maluf Coelho, Júlio César Criscuolo Boson, Nayara Peres Aguiar, Karen Bento Ribeiro, Naruna Pereira Rocha, Fernanda Carolina Camargo et al. · 2026 · Research Square
  8. Metabolic dysfunctionassociated steatotic liver disease in diabetes
    R.A. Rzayeva, N.E. Musayeva · 2026 · https //www saqlamliq
  9. Accuracy and Utility of Noninvasive Tools in Screening Adult Population for Hepatic Steatosis: A Validation Study in Southeast Rajasthan
    Preeti Gupta, Ankita Rana, Durgesh Shukla, Vivek Gupta, Vineet V. Nair, Sangeeta Saxena, Dr Anil Sharma, Ashok Sharma · 2026 · CHRISMED Journal of Health and Research
  10. Association of Lipid and Inflammatory Profiles With Tumor Stage in Hepatocellular Carcinoma
    Nan-Mu Yang, Ting Wang, Xiang-Jun Qian, Zhong-Yi Li, Hao Wang, Hang Xing, Yuan-Lin Xu, Shuai-Ya Ma, Bo Meng, Xian-Zhou Zhang et al. · 2026 · Cancer Medicine
  11. Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Jee‐Fu Huang, C Y Chen, Ming‐Jong Bair, Tzu-Chun Lin, Ming‐Lun Yeh, Pei‐Chien Tsai, Yu‐Ju Wei, Chih‐Wen Wang, Po‐Cheng Liang, Ming‐Yen Hsieh et al. · 2026 · The Kaohsiung Journal of Medical Sciences
  12. Association between metabolic risk factors and hepatocellular carcinoma: a systematic review and meta-analysis of cohort studies
    Xiaoli Yang, Peng Fu, H L Liu · 2026 · Frontiers in Medicine
  13. Evidence summary on perioperative blood glucose management in liver cancer patients
    Yuxiao Li, Ming Pang, Caifang Gong, Chuan You · 2026 · Frontiers in Oncology
  14. Prophylactic Effects of Dietary Patterns and Indexes, Nutrition and Lifestyle on Hepatocellular Carcinoma
    Zhiyuan Han, Hao Song, Cailiu Wang, Qiang Li, Youbao Ye, Wenxiu Liu, Guanglong Pang, Wanyu Sun, Xiaoyu Zhu, Sijiong Wang et al. · 2026 · Annals of Surgical Oncology
  15. Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial
    Asmaa Mohammad Ramadan, Lamia Mohamed El Wakeel, Abdulmoneim Adel, Mohamed Abdel‐Wahab, Sarah Fahmy · 2026 · BMC Gastroenterology
  16. Hepatocellular carcinoma surveillance in MASLD: from cirrhosis-based screening to personalized risk stratification
    Rosanna Villani, Gaetano Serviddio · 2026 · Annals of Hepatology
  17. Metabolic Dysfunction and Hepatocarcinogenesis: The Rising Burden of MASLD-Related HCC
    Mariana Michelle Ramírez-Mejía, Mariana Montoya-López, Sarai Gómez-Camacho, Fernanda M Martínez-Díaz, Elsie A Jiménez-Cuevas, Nahúm Méndez-Sánchez · 2026 · IntechOpen eBooks
  18. Using Homeostatic Model Assessment of Insulin Resistance to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease Risk Stratification in Individuals with Type 2 Diabetes from Primary Care and Endocrinology Settings
    NATHALY CUERVO-PARDO, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Diana Barb, Anu Sharma, Rosenberg Jens, Fernando Bril, Margery A. Connelly, Joseph R. Grajo et al. · 2026 · Endocrine Practice
  19. Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Fasiha Kanwal, Vincent Wai Sun Wong · 2026 · Wiley eBooks
  20. Taiwan GEST ‐ TASL ‐ TMASO Joint Position Statement in Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity
    Pin‐Nan Cheng, Chia‐Wen Lu, Chih Lin Lin, Chien‐Hsieh Chiang, Hwai‐I Yang, Hsiang‐Han Kao, Chia‐Chi Wang, Tzu-Jung Chou, Ming‐Ling Chang, Tun-Jen Hsiao et al. · 2026 · Liver International